| Document |
Document Title |
|
JP2003512607A |
An allosteric site on muscarinic receptors is disclosed, together with its use for screening for compounds capable of modulating the binding of a primary ligand such as acetylcholine to the receptor. The site is characterised herein a se...
|
|
JP3391539B2 |
PURPOSE: To obtain a medicine useful for preventing or treating tumors, esp. breast cancer, with no side effects, by use of a pregnane derivative having specific structure. CONSTITUTION: This medicine is obtained by use of a compound of ...
|
|
JP2003511402A |
Composition contains dehydroepiandrosterone (DHEA) and a desquamative agent.
|
|
JP2003081836A |
To provide a pharmaceutical preparation for preventing or treating hyponatremia.This pharmaceutical preparation for preventing/treating hyponatremia includes a compound of formula (I) (wherein, R1A and R1B are each H, an organic acid res...
|
|
JP2003026591A |
To provide a specific anoretic agent, to provide a method for producing the anoretic agent by its synthesis, to provide an appetite suppressant composition containing the anoretic agent, and to provide an anorexiant.A compound represente...
|
|
JP3358812B2 |
A method is provided for isolating 5,7-diene-containing steroids, particularly 3 beta -ols and esters of 3 beta -ols, from a sterol mixture. The method involves (1) treating the mixture with a dienophile or with an oxidizable dienophile ...
|
|
JP3356525B2 |
The invention relates to the compounds (I): R = oxo or beta -OH and A and B represent a free or protected 3-keto- DELTA <4> or DELTA <1,4> residue, their preparation, their application to the preparation of the compounds (A): R3 is a hyd...
|
|
JP2002540120A |
The invention relates to a method for representing compounds of the general formula (1). The invention further relates to the hitherto unknown compounds of general formulas (5, 6 and 7) in the form of intermediate products and to the use...
|
|
JP3349554B2 |
The invention relates to a new process for preparing the compounds of formula (I): in which the rings A and B represent a 3-keto- DELTA <4>-6-R3, optionally in a form protected in position 3, or 3-keto- DELTA <1,4>-6-R3, R is methyl or -...
|
|
JP2002533471A |
The invention relates to new 7 alpha , 17 alpha , 17 beta -substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-ter...
|
|
JP3328377B2 |
PURPOSE: To economically obtain the subject compd. showing therapeutic activity without producing by-products by a new method of inverting a specified starting compd. into a halohydrin, rearranging the halohydrin in the presence of an al...
|
|
JP2002531575A |
[Chemical 1] [In the formula, R1, R2And R4Are H and / or methyl, respectively, and R3Is a linear and / or branched alkyl and / or alkenyl group having 1 to 15 carbon atoms. ] With respect to sterol phosphates and their hydrides. Such ste...
|
|
JP3325026B2 |
PCT No. PCT/US94/07220 Sec. 371 Date Oct. 31, 1995 Sec. 102(e) Date Oct. 31, 1995 PCT Filed Jun. 27, 1994 PCT Pub. No. WO95/00147 PCT Pub. Date Jan. 5, 1995Compounds of formula (I), wherein: R1 is selected from the group consisting of hy...
|
|
JP2002527380A |
One aspect of the present invention is a method of human female menopause treatment which comprises subcutaneous administration of a menopausely effective amount of a hormonal replacement agent selected from the group consisting of a pro...
|
|
JP2002527448A |
This invention provides 5 alpha -pregnane-3 beta , (20S), 21-triol, 20-O- beta -glucuronide and 5 alpha -pregnane-3 beta ,20R-diol, 20-O- beta -glucuronide and pharmaceutically acceptalbe salts thereof which are useful as progestational ...
|
|
JP2002527525A |
The invention relates to a basic granulate comprising (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said granulate comprises (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pr...
|
|
JP3310301B2 |
A compound having the structure: wherein n is an integer from 1-5; each of R1 and R2 independently is optionally substituted C1-C6 alkyl; each of W and X is independently hydrogen or C1-C6 alkyl; Y is O, S or NR3 where R3 is hydrogen, C1...
|
|
JP2002205997A |
To obtain a specific anorectic agent, to provide a method for producing the anorectic agent by synthesis, to obtain an anorectic composition containing the above agent, and to provide an anorectic method.The anorectic agent is a compound...
|
|
JP3295426B2 |
Novel antihypercholesterolemic agents are provided. An exemplary group of compounds has the structural formula (I) (I) wherein R is a C-17 side chain, R1 is -OH, =O, or the like, and X and Y are CH, C-OH, C-OCH3 or C-Z. Methods of using ...
|
|
JP3281954B2 |
PCT No. PCT/FR91/00888 Sec. 371 Date Aug. 14, 1992 Sec. 102(e) Date Aug. 14, 1992 PCT Filed Nov. 12, 1991 PCT Pub. No. WO92/08730 PCT Pub. Date May 29, 1992.A process for crystallizing a pharmaceutically active steroidal product, without...
|
|
JP3279564B2 |
The present invention describes a methylating or ethylating agent containing trimethylaluminium or dimethylzinc or triethylaluminium, as source of methyl or ethyl respectively, which agent additionally contains catalytic amounts of one o...
|
|
JP2002512209A |
The invention relates to a method for carrying out photochemical and thermochemical solar syntheses by means of flat-bed solar light collectors without devices for focusing the sunlight. The method is particularly well suited for produci...
|
|
JP2002511481A |
The invention relates to a new method comprising different ways of producing compounds of formula (1). The invention further relates to the hitherto unknown compounds of formulas (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13),...
|
|
JP2002068994A |
To provide an extract and a compound obtained from a plant and having an anti-diabetes mellitus activity, and a medicinal composition, beverage and food containing them.The extract having the anti-diabetes mellitus activity is obtained f...
|
|
JP2002502423A |
The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgica...
|
|
JP2002502404A |
The invention relates to 17beta-allyloxy(thio)alkyl-androstane derivatives having general formula (I) wherein R1 is (H, OR), (H, OSO3H) or NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1...
|
|
JP2001526293A |
The invention relates to 17beta-aryl(arylmethyl)oxy(thio)alkyl-androstane derivatives having general formula (I), wherein R1 is (H,OR), (H,OSO3H) or NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydro...
|
|
JP2001328998A |
To provide a method and apparatus for separating estrone and estradiol or 17α-ethynylestradiol whose structures are extremely similar.A solution containing estradiol and estrone or a solution containing 17α-ethynylestradiol and estrone...
|
|
JP2001523268A |
This invention provides a compound having formula (I) wherein R and R<1> are each, independently, hydrogen or SO3<->X<+>; X<+> is alkali metal, alkaline earth metal, ammonium, alkylammonium containing 1-6 carbon atoms, or dialkylammonium...
|
|
JP2001261695A |
To provide both a method and an apparatus for simply concentrating a steroid in a solution.A solution containing a steroid is brought into contact with a styrene-divinylbenzene copolymer and captured. Then the captured steroid is eluted ...
|
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP3180855B2 |
PURPOSE: To provide a cockroach-collecting pheromone comprising a cockroach- attracting substance and a cockroach-restraining substance and useful as a cockroach-controlling agent extremely excellent in its controlling effect because of ...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP2001158741A |
To obtain a material capable of reducing secretion of excess gastric acid and provide a method for using the material.In this invention, to reduce secretion of gastric acid of animals including humans by using a specific extract and comp...
|
|
JP3176075B2 |
A steroid derivative of the formula (I): wherein X is hydrogen or fluorine; R<1> is hydrogen, hydroxyl or methyl; R<2> and R<3> are each independently hydrogen, hydroxy, -O(CH2)nSi(R)3 or -OCOR; R<4> is a lower alkyl having 1 to 4 carbon...
|
|
JP2001139473A |
To provide the subject medicinal composition, and to provide a method for producing the subject compound to be used in the above composition. The above compound is characterized by being pure in terms of crystal and containing entirely o...
|
|
JP3168542B2 |
The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, remo...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP3139709B2 |
A pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said compound ...
|
|
JP3128580B2 |
PURPOSE: To provide the subject compound useful as an intermediate for synthesizing catechol estrogen-3-glucosides in reduced processes in a good yield at a low cost by a specific method using an acetyl estrogen compound as a starting ra...
|
|
JP2000516625A |
(57) [Summary] The present invention relates to a method for producing eltanorone (I), which is characterized by using epi-salsa sapogenin (II) with acetic anhydride in the presence of ammonium chloride and pyridine, 3α, 26-diacetoxy-. ...
|
|
JP2000264820A |
To obtain the subject composition having high safety and excellent hair growth promoting actions and useful as medicines, cosmetics, etc., effective in improving depilation due to an aging change, etc., by including specific mucopolysacc...
|
|
JP2000239296A |
To obtain a new cytostatic agent which reduces the problems of the side effects and tolerance of carcinostatic agents conventionally used for cancer chemotherapy. This cytostatic agent is obtained by finding that the ingredients derived ...
|
|
JP2000509016A |
Disclosed are (i) compounds of a steroid, a beta-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous produc...
|
|
JP2000508333A |
The subject of the invention is the products of formula (I):in which either R1 represents halogen, hydroxyl, (C1-C8) alkyloxy or (C1-C12) acyloxy, and R2 represents halogen or hydrogen, or R1 and R2 form together a double bond, Z is chos...
|
|
JP3058710B2 |
The present invention is directed to a group of compounds which are haloethyl substituted steroidal enzyme inhibitors. These compounds are useful as aromatase, 19-hydroxylase, and aldosterone biosynthesis inhibitors.
|
|
JP3056770B2 |
Products of general formula (I): in which R1 denotes an aliphatic hydrocarbon radical, R2 and R3, which are identical or different, denote a hydrogen atom or an alkyl radical, G denotes a hydrocarbon group containing from one to eighteen...
|
|
JP3049504B2 |
Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatlc steroids and their use in treating ocular hypertension, including controlling the ocular hypertension associate...
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
|
JP3048637B2 |
PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as...
|
